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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: The objective of this study was to determine the predictive value of tei-
coplanin minimal inhibitory concentrations (MICs) for treatment failure among patients with
methicillin-resistant Staphylococcus aureus (MRSA) pneumonia.
Methods: In this study, all patients with 1 tracheal aspirates or sputum cultures positive for
MRSA admitted to the hospital between April 2011 and September 2011 were reviewed. We
enrolled patients who are 18 years of age, with a diagnosis of pneumonia, and with a receipt
of teicoplanin therapy throughout the course. The relationship between teicoplanin Etest MICs
and treatment outcomes of MRSA pneumonia was analyzed to identify the breakpoint of teico-
planin MICs influencing treatment outcomes.
Results: Of the 80 patients enrolled, 31 had a lower teicoplanin MIC level (<2.0 mg/L) and 49
had a higher MIC level (2.0 mg/L) for MRSA. The lower MIC group had a higher clinical reso-
lution rate in 14 days [24 (77.4%) vs. 23 (46.9%), pZ 0.007] and a lower treatment failure rate
at the end of teicoplanin treatment [4 (12.9%) vs. 18 (36.7%), p Z 0.020]. A comparison
between the treatment success and failure groups showed that the former had a longer dura-
tion of teicoplanin use (18.76  10.34vs.12.41  5.65 days; p Z 0.014). Results of a multivar-
iate analysis showed that teicoplanin MICs  2.0 mg/Land shorter duration of teicoplanin
therapy were independent risk factors for treatment failure.fectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street,
com (M.-H. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Influence of teicoplanin MICs on MRSA pneumonia 211Conclusion: A higher teicoplanin MIC value (2.0 mg/L) may predict the treatment failure
among patients with teicoplanin-treated MRSA pneumonia.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Staphylococcus aureus has been increasingly recognized as
an important pathogen of health careeassociated pneu-
monia (HCAP), hospital-acquired pneumonia (HAP),
ventilator-associated pneumonia (VAP), and community-
acquired pneumonia (CAP).1 Previous reports have shown
that infections due to methicillin-resistant S. aureus (MRSA)
strains had a worse prognosis than that caused by
methicillin-susceptible S. aureus (MSSA) strains.2,3 Few
studies have even stated that the possible excess mortality
is related to MRSA stains in patients who had nosocomial
pneumonia.2e5
Vancomycin has been the standard drug for the treat-
ment of serious MRSA infections since the early 1980s,
when MRSA infection became significant in the hospital
setting.6 However, several studies reported that the
activity of vancomycin for the treatment of VAP due to
S. aureus was probably suboptimal.7 Meanwhile, vanco-
mycin was reported to have a poor penetration in the
lungs,8 and was an independent risk factor of hospital
death in patients with adequately treated bacteremic
pneumonia.3 Furthermore, a study regarding the relation-
ship between vancomycin minimum inhibitory concentra-
tions (MICs) and mortality in patients with MRSA, HAP, VAP,
or HCAP infections showed that vancomycin therapy for
pneumonia caused by MRSA with an MIC value between
1 and 2 mg/L should be cautious, and alternative therapy
should be considered.9
Teicoplanin is a glycopeptide alternative to vancomy-
cin and has been widely used for the treatment of
pneumonia caused by MRSA in Europe and Taiwan. In our
recent study, we demonstrated that MRSA blood isolates
with teicoplanin MIC > 1.5 mg/L could predict a poor
outcome and higher mortality among patients with
teicoplanin-treated MRSA bacteremia.10 Following our
publication, a doubt was raised regarding the influence of
teicoplanin MICs on clinical outcomes in patients with
serious MRSA pneumonia infection. We therefore con-
ducted a 6-month retrospective cohort study to examine
MRSA respiratory isolates by Etest for identifying the
MIC breakpoint of teicoplanin influencing treatment
outcomes.Materials and methods
Settings
Chang Gung Memorial Hospital (CGMH) at Linkou is a 3715-
bed tertiary care medical center in Northern Taiwan. This
retrospective cohort study has been approved by the
Institutional Research Board of CGMH-Linkou (No. 101-
0654B).Study design and identification of patients
Between April 2011 and September 2011, all the tracheal
aspirates or sputum cultures positive for MRSA were
collected in advance and stored in skimmed milk at e70 C
before the study began. Using the computer-assisted
records of the Clinical Microbiology Laboratory, we
searched for the hospitalized patients who are 18 years of
age and whose tracheal aspirates or sputum cultures were
positive for MRSA.
Pneumonia was diagnosed according to the recommen-
dation by the American Thoracic Society (ATS) and Infectious
Diseases Society of America.11 In brief, pneumonia was
defined as the chest radiograph demonstrating new or
progressive infiltrates, aswell as at least two of the following
clinical signs12: fever (38 C) or hypothermia (<35.5 C),
abnormal white blood cell count (>12,000 cells/mm3 or
<4000 cells/mm3), oxygen desaturation, and increasing
amount of purulent sputum. MRSA pneumonia was defined as
clinical presence of pneumonia accompaniedwith a tracheal
aspirate or sputum culture positive for MRSA from 1 week
before to 3 days after the first dose of teicoplanin therapy.
Only the first episode of MRSA pneumonia was reviewed.
Tracheal aspirates and sputum specimens qualified for per-
forming cultures should have >25 neutrophils and <10
epithelial cells per low-power field onGram staining. Culture
growth was semi quantitative based on the degree of growth
or number of colonies in the primary, secondary, and tertiary
streaking zones on an agar plate.
Patients were excluded if one of the following criteria
was met: age < 18 years, receipt of teicoplanin treatment
3 days, presence of MRSA airway colonization, clinical
pulmonary infection score (CPIS)13 < 6, coexisting MRSA
bacteremia, or MRSA endovascular lesions with or without
septic emboli before pneumonia.
Patients with MRSA pneumonia were identified and their
medical records were reviewed before teicoplanin MIC data
were available. The clinical data for analysis included
demographics, comorbidities, laboratory data, disease
severity, and treatment outcomes. Patients were evaluated
for the relationship between teicoplanin MICs and treat-
ment outcomes if they had no teicoplanin allergy and
received teicoplanin therapy with an adequate dosage
throughout the treatment course. The adequate dosage of
teicoplanin administered was based on the manufacturer’s
instruction (Sanofi-Aventis, Taiwan): a loading dose of
6 mg/kg (maximum 400 mg per dose) for 3 doses 12 hours
apart and then every 24 hours, adjusted by the patient’s
renal function.
Demography and comorbidity
We categorized the enrolled patient into CAP, HAP, VAP,
and HCAP. HAP was defined as the occurrence of pneumonia
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ered if pneumonia developed more than 48 hours after
endotracheal intubation.14,16 HCAP was diagnosed on the
basis of the presence of any one of the following risk
factors: hospitalization in an acute care hospital for 2 days
or more in the preceding 90 days; residence of a nursing
home or extended care facility; chronic dialysis within 30
days; receipt of recent intravenous antibiotics, chemo-
therapy, or wound care within the past 30 days.14,17,18
Demographic data included gender and age. Comorbidities
included hypertension, diabetes mellitus, heart failure,
chronic lung diseases such as chronic obstructive pulmonary
disease (COPD) or old pulmonary tuberculosis, renal insuf-
ficiency with or without requirement of dialysis, malig-
nancies, and cerebrovascular accident. Data on fraction of
inspired oxygen (FiO2) supplement, partial pressure of
oxygen (PaO2) in arterial blood, and the white blood cell
counts within 24 hours before or after the first dose of
teicoplanin were gathered by reviewing the in-patient
medical records.
Clinical conditions and efficacy assessment
We used sequential organ failure assessment (SOFA) score
systems19 with the available clinical, laboratory, image,
and microbiological data on each enrolled patient at the
beginning of teicoplanin therapy. Findings of chest radio-
graphs, follow-up sputum culture results, and vital signs
during hospitalization were recorded. Follow-up microbial
results were not available from some patients and those
were considered as missing data in the statistical analysis.
Clinical resolution of pneumonia in 14 days was defined as
(1) improvement on the follow-up chest radiographs, or (2)
survival with stationary findings on chest radiographs and
defervescence, decreased sputum amount, or respiratory
rate less than 20 times per minute by medical records.
Defervescence was defined as afebrile status for at least 3
days. Treatment failure at the end of teicoplanin treatment
was considered if there was deterioration of the follow-up
chest radiographs with persistent MRSA-positive sputum
cultures or no clinical improvement, including fever
(38 C) or hypothermia (<35.5 C), shock status (mean
arterial pressure  70 mmHg), increasing amount of puru-
lent sputum, respiratory rate  20 times per minute, or
relapse of MRSA-positive cultures. Eradication refers to no
isolation of MRSA from the follow-up cultures done before
and 7 days after cessation of teicoplanin therapy.
Laboratory methods
S. aureus was identified according to the following findings:
aerobic,Gram-positive cocci in clusters on aGram’s stain and
a catalase-positive, coagulase-positive, and ornithine-
negative reaction.20 MRSA was identified by the detection
of oxacillin resistance with a 30-mg cefoxitin disk and Muel-
lereHinton agar according to the Clinical and Laboratory
Standards Institute recommendations.21 All the MRSA respi-
ratory isolates collected from the enrolled patients were
preserved in skimmed milk ate70 C until they were further
tested. Teicoplanin MICs were determined using Etest tei-
coplanin strips (ABBIODISK, Solna, Sweden)with an inoculumequivalent to 0.5 McFarland turbidity, braineheart infusion
agar (Oxoid, Basingstoke, UK), and incubation for 48 hours at
35e37 C. The quality control strain was MSSA ATCC 29213.
The MIC breakpoint for teicoplanin resistance is >2 mg/L in
accordance with the European Committee on Antimicrobial
Susceptibility testing (EUCAST).22
Statistical analysis
All statistical analyses were performed using the Statistical
Package for the Social Sciences for Windows (version 19;
IBM Corporation, Somers, New York, USA). Descriptive
statistics were used to summarize the continuous variables,
including the number of observations, mean, and standard
deviation. Student t test or Wilcoxon test was considered
for the test statistics, depending on the validity of the
normality assumption. Chi-square test or Fisher’s exact test
was used to test the categorical variables. Odd ratios (ORs)
and 95% confidence interval (CI) were calculated. Variables
with p < 0.2 in univariate analysis were included in
a logistic regression model for multivariate analysis. All
tests were two-tailed, and p < 0.05 was considered
significant in multivariate analysis.
Results
A total of 91 patients diagnosed with MRSA pneumonia were
identified initially. Of them, 11 patients were excluded
according to the aforementioned exclusion criteria.
Therefore, 80 patients with teicoplanin-treated MRSA
pneumonia were enrolled in this study with a mean age of
74.8 years with male predominance (81.3%). As for disease
severity, SOFA score was 6.5. The major comorbidities were
hypertension (57.5%) and diabetes mellitus (40%). Twenty-
five patients (31.3%) had chronic lung diseases, including
COPD (14, 17.5%) and old pulmonary tuberculosis (11,
13.8%). Thirty-four patients (42.5%) had polymicrobial
pulmonary infections and the mean duration of teicoplanin
use was 17.01 days.
Of these 80 patients, 31 had MRSA isolates with teicopla-
ninMICs<2.0mg/Land49had those isolateswith teicoplanin
MICs 2.0 mg/L. They were divided into the lower MIC
(<2.0 mg/L) and higher MIC (2.0 mg/L) groups. The
comparison of their demographics, comorbidities, labora-
tory data, disease severity, and treatment outcomes is
summarized in Table 1. There was no significant difference
between these twogroupswith respect to the demographics,
comorbidities, lab data, disease severity, crude mortality,
and microbial eradication. Compared with the higher MIC
group, the lower MIC group had a higher clinical resolution
rate in 14 days [24 (77.4%) vs. 23 (46.9%); p Z 0.007] and
a lower treatment failure rate at the endpoint of teicoplanin
therapy [4 (12.9%) vs. 18 (36.7%); pZ 0.020].
To identify risk factors for treatment failure at the
endpoint of teicoplanin therapy, these 80 patients were
divided into the treatment success and treatment failure
groups (Table 2). There were no statistical differences
between these two groups in age, gender, source of pneu-
monia, underlying diseases, and initial disease severity
while MRSA pneumonia was diagnosed. Compared with the
failure group, patients with treatment success had a longer
Table 1 Comparison of clinical characteristics of patients with methicillin-resistant Staphylococcus aureus pneumonia
between the groups of teicoplanin MICs < 2.0 mg/L and  2.0 mg/L
Variables MIC < 2.0 mg/L
(n Z 31)
MIC  2.0 mg/L
(n Z 49)
p
Demographics
Gender (male) 26 (83.9) 39 (79.6) 0.633
Age (year) 76.15  12.81 73.94  15.92 0.517
Community-acquired pneumonia 5 (16.1) 8 (16.3) 0.981
Hospital-acquired pneumonia 26 (83.9) 41 (83.7) 0.981
Ventilator-associated pneumonia 12 (38.7) 15 (30.6) 0.456
Health careeassociated pneumonia 5 (16.1) 5 (10.2) 0.498
Comorbidities
Hypertension 20 (64.5) 26 (53.1) 0.313
Diabetes mellitus 13 (41.9) 19 (38.8) 0.779
Congestive heart failure 9 (29.0) 7 (14.3) 0.108
Chronic obstructive pulmonary disease 3 (9.7) 11 (22.4) 0.143
Old pulmonary tuberculosis 5 (16.1) 6 (12.2) 0.742
Chronic renal failure without dialysis 9 (29.0) 11 (22.4) 0.508
End-stage renal disease 5 (16.1) 6 (12.2) 0.742
Malignancies 7 (22.6) 14 (28.6) 0.553
Cerebrovascular accident 11 (35.5) 18 (36.7) 0.910
Laboratory data
FiO2 51.13  24.66 42.14  17.26 0.082
PaO2 109.70  55.67 91.15  36.67 0.107
Creatinine (mg/dL) 1.83  2.15 2.08  2.07 0.605
White blood cell count (cells/mm3) 15,803.23  8209.69 14,987.76  6643.31 0.627
Disease severity
SOFA score 6.65  2.89 6.41  3.53 0.755
Stay in intensive care unit (ICU) 18 (58.1) 27 (55.1) 0.795
Treatment outcome
Treatment duration (days) 16.74  8.69 17.16  10.37 0.851
Clinical resolution in 14 days 24 (77.4) 23 (46.9) 0.007
Clinical resolution in 28 days 21 (67.7) 26 (53.1) 0.194
Treatment failure 4 (12.9) 18 (36.7) 0.020
Crude mortality 14 (45.2) 24 (49.0) 0.739
Mortality before 14th day 5 (16.1) 5 (10.2) 0.498
Mortality before 28th day 9 (29.0) 17 (34.7) 0.598
Microbial eradicationa 13/22 (59.1) 13/30 (43.3) 0.262
a Microbial eradication: only 52 patients had subsequent follow-up respiratory tract cultures, 22 in the low MIC group, and 30 in the
higher MIC group.
Categorical data are the number (%) of subjects, and continuous data are expressed as mean  standard deviation.
MIC Z minimal inhibitory concentration; FiO2 Z fraction of inspired oxygen; PaO2 Z partial pressure of oxygen in arterial blood;
SOFA Z sequential organ failure assessment.
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days; p Z 0.014). Multivariate analysis showed that the
teicoplanin MIC  2.0 mg/L (adjusted OR, 4.58; 95% CI:
1.261e16.646) and treatment duration (adjusted OR, 0.89;
95% CI: 0.822e0.971) were independent risk factors for
treatment failure at the endpoint of teicoplanin therapy
(Table 3). The survival analysis for MRSA pneumonia with
teicoplanin MIC < 2 mg/L and  2.0 mg/L (p Z 0.201) is
presented in Fig. 1.
Microbiological outcome
In our study, only 52 patients had subsequent follow-up
respiratory tract cultures available for evaluation ofmicrobiological outcomes. Among them, the lower MIC
group had a better eradication rate of MRSA (13/22, 59.1%)
than the higher one (13/30, 43.3%) (Table 1). However,
there was no significant difference between them.
Discussion
A systematic review in 1999 revealed that inadequate
antimicrobial treatment of patients requiring intensive care
unit (ICU) admission was an important determinant of
hospital mortality.23 Inadequate antimicrobial treatment
included the absence of antimicrobial agents for a specific
class of microorganisms and the administration of an anti-
microbial agent which was not active in vitro against the
Table 2 Univariate analysis of risk factors for treatment failure
Variables Treatment success
(n Z 58)
Treatment failure
(n Z 22)
p
Demographic
Gender (male) 48 (82.8) 17 (77.3) 0.749
Age (year) 76.27  14.01 70.91  16.23 0.180
Community-acquired pneumonia 8 (13.8) 5 (22.7) 0.331
Hospital-acquired pneumonia 50 (86.2) 17 (77.3) 0.331
Comorbidities
Hypertension 37 (63.8) 9 (40.9) 0.683
Diabetes mellitus 24 (41.4) 8 (36.4) 0.683
Congestive heart failure 11 (19.0) 5 (22.7) 0.733
Chronic obstructive pulmonary disease 11 (19.0) 3 (13.6) 0.747
Old pulmonary tuberculosis 7 (12.1) 4 (18.2) 0.483
Chronic renal failure without dialysis 13 (22.4) 7 (31.8) 0.386
End-stage renal disease 9 (15.5) 2 (9.1) 0.718
Malignancies 13 (22.4) 8 (36.4) 0.205
Cerebrovascular accident 22 (37.9) 7 (31.8) 0.612
Laboratory data
FiO2 44.91  20.53 47.50  21.75 0.622
PaO2 99.96  43.51 94.05  51.44 0.607
Creatinine (mg/dL) 1.95  2.10 2.07  2.09 0.818
White blood cell count (cells/mm3) 15,358.62  7693.38 15,159.09  6089.23 0.913
Disease severity
SOFA score 6.33  3.32 6.95  3.21 0.449
Stay in intensive care unit (ICU) 32 (55.2) 13 (59.1) 0.752
Treatment
Treatment duration (days) 18.76  10.34 12.41  5.65 0.014
Categorical data are the number (%) of subject, and continuous data are expressed as mean  standard deviation.
FiO2 Z fraction of inspired oxygen; PaO2 Z partial pressure of oxygen in arterial blood; SOFA Z sequential organ failure assessment.
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nin treatment for MRSA pneumonia was excluded in our
study because of the real-time online hospital-wide
computerized antimicrobial approval system (HCAAS) at
CGMH-Linkou.24 In brief, any antibiotic prescribed by the
physicians in our hospital will be reviewed by Infectious
Diseases specialists online in time. All the patients’ elec-
tronic medical records, laboratory data, procedure exami-
nation, and image studies are available to check from the
HCAAS. This strategy is to monitor whether the prescribed
antimicrobial regimens were rational or not.Table 3 Multivariate analysis of risk factors associated
with treatment failure
OR 95% CI p
MIC  2.0 mg/L 4.581 1.261e16.646 0.021
Treatment duration 0.893 0.822e0.971 0.008
Age 0.970 0.935e1.007 0.109
Risk factors with p < 0.2 in univariate analysis in Table 2 and the
factor of MIC  2.0 mg/L were considered for inclusion in
a multivariate analysis.
CI Z confidence interval; MIC Z minimum inhibitory concen-
tration; OR Z odds ratio.There were substantial differences in clinical charac-
teristics between the treatment success and failure groups.
The unadjusted creatinine levels, oxygen supplement, and
disease severity scoring systems such as SOFA score, CPIS,
and ICU admission rate were higher in the treatment failure
group although there were no statistical differences in the
univariate analysis. As reported previously, MRSA infection
was more common among patients with worse severity
scores, infections in ICU, or MRSA carriage.5
Several studies have demonstrated the relationship
between glycopeptide MICs and treatment failure in
patients with MRSA infections. A study conducted by
Charlesworth et al showed that a higher teicoplanin MIC, as
found by Etest or agar incorporation, was associated with
a lower survival rate in critically ill patients.25 A couple of
other studies reported that a vancomycin MIC val-
ue > 1.5 mg/L was associated with a higher rate of treat-
ment failure and a higher 30-day mortality.26,27 In a recent
study by Chang et al, a higher teicoplanin MIC value
(>1.5 mg/L) may be associated with unfavorable outcomes
and higher mortality among patients with teicoplanin-
treated MRSA bacteremia.10 Thus, we focused on patients
with MRSA pneumonia and chose the teicoplanin MIC value
of 2.0 mg/L as the cutoff value. This study revealed that
a lower teicoplanin MIC value (<2.0 mg/L) for MRSA was
associated with a higher clinical resolution rate in 14 days
Figure 1. Survival analysis of patientswith pneumonia caused
by methicillin-resistant Staphylococcus aureus with teicoplanin
minimum inhibitory concentrations (MICs) < 2.0 mg/L
and  2.0 mg/L (pZ 0.201).
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teicoplanin-treated MRSA pneumonia. Multivariate analysis
showed that higher teicoplanin MIC value (2.0 mg/L) and
shorter teicoplanin treatment duration were independent
risk factors for treatment failure at the endpoint. This
result was similar to the findings of Haque et al, who
described that the mortality of patients with MRSA pneu-
monia treated with vancomycin would increase with
elevated vancomycin MIC values.9The MRSA eradication
rate in respiratory tract was low in this study, but the
microbial eradication was not significantly associated with
clinical outcomes.
There were some limitations in our study. First, there
were some patients with incomplete follow-up data for
sputum cultures because all the airway cultures were
requested by clinicians based on their discretion. Second,
no molecular analysis for epidemiological survey was per-
formed to identify the specific MRSA strains. MRSA strains
with specific resistant genes could influence MIC
values.28,29 Besides, some experts recommended that
a higher loading dose of teicoplanin (e.g., 12 mg/kg) may
correlate with a better outcome or a higher serum level.30
However, there was no case undertaken with such a dose in
our study. Finally, many patients had polymicrobial isolates
from airway cultures and received other broad-spectrum
antibiotic therapy while receiving teicoplanin. These
combination therapeutic regimens may impact the efficacy
of teicoplanin therapy.
In conclusion, our study affords preliminary evidence
that the teicoplanin Etest MIC cutoff value of 2.0 mg/L
could be a predictive value for clinical outcomes among
patients with teicoplanin-treated MRSA pneumonia, and
even the teicoplanin MICs for MRSA isolates are still within
the susceptible breakpoint according to EUCAST criteria in
2011. The independent risk factors for treatment failure
were higher teicoplanin MIC value (2.0 mg/L) for MRSA
and shorter duration of teicoplanin therapy. The assess-
ment of the changes of teicoplanin MIC values should be
taken into consideration, especially among patients who
underwent teicoplanin treatment without clinical resolu-
tion. Other alternative therapies should be seriously
considered for the MRSA isolates with teicoplanin
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